SAGE Therapeutics (SAGE)

SAGE Therapeutics (SAGE) Stock Price & Analysis


SAGE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$30.67 - $57.02
Previous Close$56.7
Average Volume (3M)516.99K
Market Cap
Enterprise Value$2.27B
Total Cash (Recent Filing)$1.13B
Total Debt (Recent Filing)$10.45M
Price to Earnings (P/E)-6.0
Aug 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.37
Shares Outstanding59,762,106
10 Day Avg. Volume455,797
30 Day Avg. Volume516,992
Standard Deviation0.16
Financial Highlights & Ratios
Price to Book (P/B)2.99
Price to Sales (P/S)1028.69
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue241.47
Enterprise Value/Gross Profit295.26
Enterprise Value/Ebitda-3.92
Price Target Upside-1.06% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $30.66 and its highest was $57.02 in the past 12 months.
    What is SAGE Therapeutics’s market cap?
    Currently, no data Available
    When is SAGE Therapeutics’s upcoming earnings report date?
    SAGE Therapeutics’s upcoming earnings report date is Aug 08, 2023 which is in 59 days.
      How were SAGE Therapeutics’s earnings last quarter?
      SAGE Therapeutics released its earnings results on May 02, 2023. The company reported -$2.46 earnings per share for the quarter, beating the consensus estimate of -$2.507 by $0.047.
        Is SAGE Therapeutics overvalued?
        According to Wall Street analysts SAGE Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does SAGE Therapeutics pay dividends?
          SAGE Therapeutics does not currently pay dividends.
          What is SAGE Therapeutics’s EPS estimate?
          SAGE Therapeutics’s EPS estimate is -$2.57.
            How many shares outstanding does SAGE Therapeutics have?
            SAGE Therapeutics has 59,762,108 shares outstanding.
              What happened to SAGE Therapeutics’s price movement after its last earnings report?
              SAGE Therapeutics reported an EPS of -$2.46 in its last earnings report, beating expectations of -$2.507. Following the earnings report the stock price went down -6.353%.
                Which hedge fund is a major shareholder of SAGE Therapeutics?
                Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 18M.


                  SAGE Therapeutics Stock Smart Score

                  The SAGE Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  SAGE Therapeutics

                  SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.


                  Top 5 ETFs holding SAGE

                  Market Value
                  Smart Score
                  iShares Biotechnology ETF
                  Vanguard Health Care ETF
                  Alpha Architect U.S. Quantitative Momentum ETF
                  iShares NASDAQ US Biotechnology UCITS ETF
                  Fidelity MSCI Health Care Index ETF
                  Up to five ETFs with an Outperform Smart Score that hold SAGE. The ETFs are listed according to market value of SAGE within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  ACADIA Pharmaceuticals
                  Akero Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis